Stable vWF Binder Formulations Using Citrate Buffer and Sucrose
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of vWF binders, such as ALX-0081, face challenges with stability, particularly requiring refrigeration for storage and necessitating multiple subcutaneous injections due to low concentration, and suffer from chemical modifications that affect potency at elevated temperatures.
Innovation Solution
A citrate buffer-based formulation with sucrose and Tween-80, maintaining a pH of 6.0 to 7.0, which stabilizes vWF binders, allowing concentrations up to 80 mg/mL and retaining 80% stability after 12 months at 5°C or 24 months at 5°C, with minimal oxidation and aggregation, suitable for both liquid and lyophilized forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional formulations are used, then refrigeration is required for storage, but this reduces ease of operation and increases storage complexity
Solution Approach 1:
The patent changes the chemical parameters of the formulation by introducing a specific buffer system (phosphate-buffered saline with glycine) and surfactant (Tween-80) at optimized concentrations. These parameter changes enable the formulation to maintain stability at higher temperatures, eliminating the need for refrigeration and improving storage convenience while maintaining reliability.
Solution Approach 2:
The patent uses Tween-80 surfactant and glycine as intermediary substances that mediate between the protein drug and the storage environment. These intermediaries protect the protein from degradation and aggregation, enabling stable storage without refrigeration by creating a protective microenvironment around the active pharmaceutical ingredient.
2Volume of moving object
If low concentration formulations are used, then injection volume is reduced, but multiple injections are required reducing productivity
Solution Approach 1:
The patent changes the concentration parameter of the formulation to 5 mg/mL, which is optimized to allow higher loading per injection while maintaining stability. This parameter change enables single injection treatment, improving productivity without requiring excessively large injection volumes, thus resolving the contradiction between injection volume and treatment efficiency.
3Adaptability or versatility
If elevated temperature storage is attempted, then storage flexibility is improved, but chemical modifications occur reducing reliability
Solution Approach 1:
The patent uses the buffer system (phosphate-buffered saline with glycine) and Tween-80 surfactant as intermediary protective agents. These intermediaries create a stable microenvironment that protects the protein from thermal degradation and chemical modifications, enabling storage flexibility at elevated temperatures while maintaining potency retention and reliability.
Solution Approach 2:
The formulation includes stabilizing agents (glycine and Tween-80) that provide beforehand cushioning against thermal stress and chemical degradation. These protective components are built into the formulation in advance to cushion the protein drug against the harmful effects of elevated temperature storage, preventing potency loss before it occurs.
4Productivity
If higher concentrations are used, then fewer injections are needed improving productivity, but solubility and stability become problematic
Solution Approach 1:
The patent optimizes the concentration parameter to 5 mg/mL and adjusts other formulation parameters including buffer composition (phosphate-buffered saline with glycine) and surfactant concentration (Tween-80). These coordinated parameter changes enable the formulation to achieve higher productivity through reduced injection frequency while maintaining solubility and stability, resolving the contradiction between treatment efficiency and formulation stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides enhanced stability and solubility, reducing the need for refrigeration and allowing higher concentrations, maintaining potency and binding activity, and preventing chemical modifications, thus improving patient convenience and storage stability.
Implementation Method 1
A citrate buffer-based formulation with pH of 6.0 to 7.0, which stabilizes vWF binders
Implementation Method 2
A citrate buffer-based formulation with sucrose and Tween-80, maintaining a pH of 6.0 to 7.0, which stabilizes vWF binders, allowing concentrations up to 80 mg/mL and retaining 80% stability after 12 months at 5°C or 24 months at 5°C, with minimal oxidation and aggregation
Implementation Method 3
A citrate buffer-based formulation with sucrose and Tween-80, maintaining a pH of 6.0 to 7.0, which stabilizes vWF binders
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The present invention relates to stable formulations of polypeptides, e.g. immunoglobulin single variable domains, in particular immunoglobulin single variable domains directed against von Willebrand Factor (vWF). The invention provides formulations which are stable upon storage for prolonged periods of time and over a broad range of temperatures. The formulations of the invention ensure a high stability of the polypeptide, allowing multiple freeze-thaw cycles without chemical or physical deterioration, and provide stability in relation to mechanical stress, such as shake, shear or stir stress. They are suitable for pharmaceutical and diagnostic preparations and compatible with pharmaceutically acceptable diluents.